|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples.
|
30799393 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Basal-like breast carcinomas are characterized by high expression of basal cytokeratins; low or absent expression of estrogen receptor, progesterone receptor, and HER2/neu; and expression of epidermal growth factor receptor (EGFR) and/or c-kit, and they are frequently associated with breast cancer 1 (BRCA1) mutations and poor clinical outcome.
|
20073617 |
2010 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that two EGFR functional polymorphisms, a (CA)n repeat in intron 1, and a single nucleotide polymorphism, R497K, may affect EGFR expression and breast cancer clinical profile.
|
24629097 |
2014 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to investigate the heterogeneity of the EGFR gene copy number in breast carcinomas.
|
16138375 |
2005 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
P-cadherin, Vimentin and CK14 can recognize BLBC already identified in triple negative/ CK5 and/or EGFR+ tumors, and due to P-cadherin sensitivity for BLBC identification this marker can reliably recruit a large number of breast carcinomas with basal phenotype among immunohistochemistry triple negative/ CK5 and/or EGFR - pool of tumors.
|
20552547 |
2010 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this issue of the JCI, two reports provide intriguing new information on the role of the inflammatory cytokine IL-6 in breast and lung cancer.The study by Sansone et al. implicates IL-6 in the instigation of malignant properties in breast cancer stem cells (see the related article beginning on page 3988).The study by Gao et al. identifies mutant variants of EGFR as inducers of IL-6 in lung adenocarcinomas (see the related article beginning on page 3846).
|
18060028 |
2007 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Some of the important mutations include epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in small cell lung cancer, human epidermal growth factor receptor (HER2) mutation in breast cancer, and BRAF mutation in melanoma.
|
30771009 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although members of the EGFR family are known to form heterocomplexes with one another, c-Src has also been shown to physically interact with members of this family in breast cancer cell lines and tumors.
|
17173075 |
2007 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, and Mec-3 domain only 4 (LMO4) in pretreatment tumor samples from 91 erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations in whom breast cancer gene 1 (BRCA1) expression and the concomitant presence of the EGFR T790M mutation had previously been assessed.
|
23407556 |
2013 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
(CA)n microsatellite polymorphism of ERBB-1 in breast cancer.
|
16765588 |
2006 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, EGFR-mutations have been reported to be rare if not absent in human BC, although recent evidence has suggested a significant worldwide variation in somatic EGFR-mutations.
|
26267891 |
2015 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EGFR gene analysis of breast cancer lesion revealed no mutations.
|
30453894 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification.
|
11250708 |
2000 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Primary tumor patients with a subsequent brain relapse showed almost equally high frequencies of especially EGFR and PTEN alteration as the breast cancer brain metastases patients.
|
23665199 |
2013 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the EGFR intron 1 polymorphism may influence response to treatment with tyrosine kinase inhibitors in breast cancer patients and further studies are warranted.
|
17102595 |
2006 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we showed that the rates of EGFR and AKT1 gene copy number alterations were associated with the prognosis of breast cancer.
|
25702787 |
2015 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although basal transcription repression was impaired and the pro-metastatic protein osteopontin was differentially down-regulated by BRMS1(L174D) and BRMS1(DeltaCC1), both down-regulated the epidermal growth factor receptor and suppressed metastasis in MDA-MB-231 and -435 breast cancer xenograft models.
|
18211900 |
2008 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors of this report investigated the relation of EGFR mutation or ALK rearrangement status and the expression of DNA repair or synthesis genes, including excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthetase (TS), and breast cancer-early onset (BRCA1), as a potential explanation for these observations.
|
22569898 |
2012 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study proposed to investigate the relationship of PIK3CA somatic mutations, the most common activating mutations in human breast cancer (BC), and the efficacy of neoadjuvant chemotherapy (NCT).Using a novel liquid chip technology,PIK3CA DNA somatic mutations and HER2, PTEN, EGFR mRNA expression profiles were analyzed in formalin fixed paraffin embedded samples of 93 BC patients treated with epirubicin plus docetaxel NCT.PIK3CA mutations were found in 30 patients (32.3%), in which the point mutations of E542K, E545K, H1047L and H1047R were 4.3, 9.7, 4.3 and 14.0%respectively.
|
25027743 |
2014 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Investigating the function of three non-synonymous SNPs in EGFR gene: structural modelling and association with breast cancer.
|
20049516 |
2010 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
|
30407790 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No EGFR or KIT activating mutations were present; 26% of the primary metaplastic breast carcinomas were fluorescence in situ hybridization-positive, displaying high EGFR copy number secondary to aneusomy (22%) and amplification (4%).
|
18413808 |
2008 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The EGFR L858R antibody gives false-positive results in most of the breast carcinomas with HER2 overexpression/amplification.
|
25390349 |
2015 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
More and more evidences demonstrate that androgen receptor (AR), epidermal growth factor receptor (EGFR), and breast cancer susceptibility gene 1 (BRCA1) have unique clinical implications for targeted therapy or prognosis in triple-negative breast cancer (TNBC).
|
25695063 |
2015 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements.
|
25257380 |
2015 |